Welcome to our dedicated page for Kiniksa Pharmaceuticals International news (Ticker: KNSA), a resource for investors and traders seeking the latest updates and insights on Kiniksa Pharmaceuticals International stock.
Kiniksa Pharmaceuticals International, plc develops and commercializes novel therapies for diseases with unmet need, with a focus on cardiovascular indications. News about Kiniksa commonly covers ARCALYST (rilonacept), an IL-1α and IL-1β cytokine trap approved by the FDA for recurrent pericarditis and other autoinflammatory indications.
Company updates also address ARCALYST commercial performance, patient-awareness initiatives in recurrent pericarditis, quarterly and annual financial results, and portfolio execution. Additional recurring themes include the KPL-387 recurrent pericarditis program, KPL-1161 IL-1 receptor antagonist development, corporate updates, and healthcare conference presentations.
Kiniksa Pharmaceuticals (Nasdaq: KNSA) announced that its management will participate in a fireside chat at the Canaccord Genuity 46th Annual Growth Conference on Wednesday, August 12, 2026 at 9:00 a.m. Eastern Time. A live webcast and replay will be available in the Investors section of Kiniksa’s website.
Kiniksa Pharmaceuticals (Nasdaq: KNSA) reported Q2 2026 total revenue of $243.6 million, all from ARCALYST, up about 55% year over year. Net income was $25.4 million versus $17.8 million a year earlier, with operating expenses rising to $216.4 million.
ARCALYST Q2 net product revenue was $243.6 million, and 2026 net product revenue guidance was raised to $980–$995 million, from $930–$945 million, according to Kiniksa. Cash, cash equivalents, and short-term investments were $525.9 million with no debt as of June 30, 2026.
KPL-387 Phase 2 data in recurrent pericarditis showed rapid median time to treatment response of 4 days at 300 mg SC monthly, supporting this dose for the pivotal Phase 3 PASTORALE trial, which is now enrolling. Kiniksa also plans to start a Phase 1 trial of KPL-1161 by year-end 2026.
Kiniksa Pharmaceuticals (Nasdaq: KNSA) will host a conference call and live webcast on Tuesday, July 28, 2026 at 8:30 a.m. Eastern Time to report its second quarter 2026 financial results and recent portfolio execution. The live webcast and replay will be available via the Investors & Media section of Kiniksa’s website.
Kiniksa Pharmaceuticals (Nasdaq: KNSA) announced management will participate in investor fireside chats at two June 2026 healthcare conferences: the Jefferies Global Healthcare Conference on June 3 at 8:45 a.m. ET and the Goldman Sachs 47th Annual Global Healthcare Conference on June 9 at 11:20 a.m. ET.
Live webcasts and replays will be available via the Investors & Media section of Kiniksa's website.
Kiniksa Pharmaceuticals (Nasdaq: KNSA) reported Q1 2026 results with ARCALYST net product revenue of $214.3M, a 56% year-over-year increase, and raised 2026 ARCALYST guidance to $930–$945M. Q1 net income was $22.6M. Cash and short-term investments totaled $468.1M with no debt. Clinical milestones: KPL-387 Phase 2 data expected in 2H 2026 and Phase 3 initiation targeted by year-end; KPL-1161 Phase 1 planned by end of 2026.
Kiniksa Pharmaceuticals (Nasdaq: KNSA) will report first quarter 2026 financial results on April 28, 2026 with a conference call and live webcast at 8:30 a.m. ET.
Telephone registration is required; webcast and a replay (available ~48 hours after the event) will be accessible via the company website.
Kiniksa (Nasdaq: KNSA) launched Heart’s Home, a targeted Direct-to-Consumer TV campaign for ARCALYST (rilonacept) on April 8, 2026. The campaign targets patients with recurrent pericarditis (about 40,000 U.S. patients yearly), is live on connected TV and streaming, and includes digital and social components. ARCALYST is the first-and-only FDA approved therapy to treat recurrent pericarditis and reduce recurrence risk in patients aged 12+, administered as a weekly subcutaneous injection blocking IL-1α and IL-1β.
Kiniksa Pharmaceuticals (Nasdaq: KNSA) announced management will participate in a fireside chat at the TD Cowen 46th Annual Health Care Conference on March 2, 2026 at 3:10 p.m. ET. A live webcast will be available via the Investors section of Kiniksa's website, with a replay posted within approximately 48 hours.
Kiniksa Pharmaceuticals (Nasdaq: KNSA) reported Q4 2025 ARCALYST net product revenue of $202.1M and full-year 2025 ARCALYST revenue of $677.6M, a 62% year-over-year increase. The company expects 2026 ARCALYST revenue of $900–$920M and plans KPL-387 Phase 2 data in 2H 2026 and a KPL-1161 Phase 1 start by end of 2026. Cash rose by $170.4M to $414.1M and full-year 2025 net income was $59.0M.
Kiniksa Pharmaceuticals (Nasdaq: KNSA) will report its fourth quarter and full year 2025 financial results on Tuesday, February 24, 2026.
The company will host a conference call and live webcast at 8:30 a.m. ET. A live webcast will be available via the Investors & Media section of the company's website, and a replay will be posted approximately 48 hours after the event. Telephone participants must register to receive dial-in details and a unique passcode.